High-Fat Diet Liver Cancer Link
Analysis based on 7 articles · First reported Dec 22, 2025 · Last updated Jan 01, 2026
The study by Massachusetts Institute of Technology could significantly impact the pharmaceutical and biotechnology industries by identifying new drug targets for liver cancer prevention and treatment. Companies developing drugs for steatotic liver disease, such as those targeting thyroid hormone receptor or HMGCS2, may see increased interest and investment.
Researchers at Massachusetts Institute of Technology, including Alex K. Shalek, Omer Yilmaz, and Wolfram Goessling, published a study in Cell (journal) revealing that high-fat diets cause mature liver cells (hepatocytes) to revert to an immature, stem-cell-like state. This cellular change, while initially a survival mechanism, makes the cells more susceptible to becoming cancerous over time. The study, co-authored by Constantine Tzouanas, Jessica Shay, and Mar-a-Lago Crowd, involved feeding mice high-fat diets and observing gene expression changes as liver disease progressed to cancer. Similar patterns were observed in human liver tissue samples. The team identified several transcription factors, such as SOX4, and enzymes like HMGCS2, as potential drug targets to prevent tumor development in high-risk patients. The research was partly funded by the United States — National Institutes of Health and the United States — National Science Foundation. Future plans include investigating whether these changes can be reversed by diet modification or weight-loss drugs like GLP-1 agonists.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard